Search Result for : Bioasia

Automation, H1-B, ebbing growth: Culprits of layoffs in Indian IT

The Dollar Business Bureau As growth slows for India’s $150 billion IT industry, many IT majors have begun to lay-off mid and senior level employees to account for tapering revenue growth. The probable tightening of H1-B visas under Trump’s reign is also a strong motivator for companies to hire locally for projects based outside India. The global and domestic factors have together concocted a nightmare for IT professionals in India. As a result of automation and increasing use of bots, fruits of cutting edge research in machine learning and artificial intelligence, the IT industry is well poised to replace a huge chunk of its human capital with machines. The threat, which commentators have been worrying about for more than a decade, is ...

Thought-provoking pharma initiatives at Bio Asia 2017

Vijay Bhanu On the third day of Bio Asia 2017, major pharmaceutical company CEOs and various healthcare representatives reached out to the visitors, detailing the products and initiatives taken up by their respective companies. At the grand exhibit, Medi Tox CEO Jan Zábský, spelt out the initiatives that his company was into. Medi Tox is actively into pre-clinicalR&D of drugs associated with cardiovascular disorders, anti-influenza vaccines, neurodegenerative diseases, oncology, ophthalmology and diabetes. Their speciality products include therapeutics for animals like monkeys, dogs, pigs, etc. Zábský claimed that 10% of the company’s customers are in the Czech Republic and another 10% in India. He welcomed visitors and dispersed product information enthusiastically. Habib, a member of IIT fellowship, said that the Center of Healthcare Entrepreneurship (CFHE), situated within the IIT Hyderabad campus, conducts fellowship programmes for research in bio-design process and various major health issues plaguing the society. Talking about the programme, he said that it offers a platform for those concentrating ...

'The present government has realised that ObamaCare can't be repealed', Matt Szuhaj, MD, Deloitte

Sneha Gilada Pharmaceuticals contribute as much as 5% to all Indian exports, and US is the biggest export market for Indian pharma, contributing one-third of total pharma exports. Naturally, the big names in Indian pharma are experiencing jitters from Trump's recent protectionist utterances.  At Bio Asia 2017, in an exclusive with Matt Szuhaj, MD, Deloitte Consulting LLP, San Francisco, The Dollar Business explores the extent of disruption the new political developments in America could cause. What is the present corporate tax scenario in USA?  Let me give you a broader context. Outside of the administration change in US, there was an effort by the OECD countries called base erosion and profit shifting. This was a process of trying to harmonise tax codes between countries. Essentially, they wanted more visibility, more transparency, and less individual agreements for specific ...

Bio Asia 2017: Power of the past, force of the future

Sneha Gilada Bio Asia 2017, a global healthcare exhibition and conference, started on February 6, 2017, here in  Hyderabad. The three day event was inaugurated by the Telangana Governor ESL Narsimhan. Early into the second day of Bio Asia, packed halls witnessed eminent speakers from the pharma industry sharing their future vision for the global healthcare sector. The 14th edition of Bio Asia, as the theme suggests, was a platform for delegates, coming from more than 50 countries, to collaborate and leverage India's potential in achieving quality healthcare for billions all over the world. Dr. Paul Stoffels, Worldwide Chairman of Pharma, Johnson & Johnson(J&J) The must-attend event for any healthcare enthusiast saw participation from more than 800 corporates, and over 100 high-profile speakers. The morning session on February 7 had a special address from the likes of  Dr. Paul Stoffels, Worldwide Chairman ...

Clinical trials in India present a great opportunity: Expert

Japan has already emphasized on the necessity of more clinical research which is being done by foreign companies. In India there have been some commendable work done on this front and Rota Vaccine is a great accomplishment on those lines. Jayarama Emani | The Dollar Business Sponsored by Thailand and co-sponsored by the United Kingdom, BioAsia 2015 scheduled from February 2 to 4, 2015 under the theme of ‘New Era of Life sciences - Opportunities in Transition’ in Hyderabad is scheduled to provide an opportunity to explore business partnerships between the industry and academia. BioAsia’s conferences will cover contemporary developments in research and will assist in building technology capabilities for Life sciences & Medical sciences sector. The conference will witness ...